Investors who own more than 5% of a class must file a Schedule 13D or 13G. Each filer's latest filing for 28036F105 since 12/18/2024, largest first.
| Filer | % of Class | Filed | ||
|---|---|---|---|---|
|
Orbimed Advisors LLC
13D/A
|
14.5% |
5/12/2025
Event 5/9/2025
|
||
| Orbimed Advisors LLC | 14.5% | |||
| Orbimed Capital GP VI LLC | 14.1% | |||
| OrbiMed Genesis GP LLC | 0.4% | |||
| Orbimed Capital LLC | 0.3% | |||
|
Paradigm Biocapital Advisors LP
13G/A
|
9.5% |
8/14/2026
Event 6/30/2026
|
||
| Paradigm BioCapital Advisors LP | 9.5% | |||
| Paradigm BioCapital Advisors GP LLC | 9.5% | |||
| Senai Asefaw, M.D. | 9.5% | |||
| Paradigm BioCapital International Fund Ltd. | 8.3% | |||
|
RA Capital Management, L.P.
13G/A
|
7.8% |
8/14/2026
Event 6/30/2026
|
||
| RA Capital Management, L.P. | 7.8% | |||
| Peter Kolchinsky | 7.8% | |||
| Rajeev Shah | 7.8% | |||
| RA Capital Healthcare Fund, L.P. | 7.8% | |||
| Janus Henderson Group PLC 13G | 5.5% |
5/15/2026
Event 3/31/2026
|
||
| BlackRock, Inc. 13G/A | 5.5% |
7/17/2025
Event 6/30/2025
|
||
|
FMR LLC
13G
|
5.1% |
8/6/2026
Event 6/30/2026
|
||
| FMR LLC | 5.1% | |||
| Abigail P. Johnson | 5.1% | |||
| Under 5%, checked the "5 percent or less" box, or amended by a later filing (3) | ||||
| Novo Holdings A/S 13D/A | 4.9% |
4/27/2026
Event 4/23/2026
|
||
|
Perceptive Advisors LLC
13G/A
|
4.4% |
8/14/2025
Event 6/30/2025
|
||
| Perceptive Advisors LLC | 4.4% | |||
| Joseph Edelman | 4.4% | |||
| Perceptive Life Sciences Master Fund, Ltd. | 4.4% | |||
|
Baker Bros. Advisors LP
13G/A
|
3.4% |
8/14/2026
Event 6/30/2026
|
||
| Baker Bros. Advisors LP | 3.4% | |||
| Baker Bros. Advisors (GP) LLC | 3.4% | |||
| Julian C. Baker | 3.4% | |||
| Felix J. Baker | 3.4% | |||
| Period | Filings | Shares, Excl. Options | Value, Excl. Options |
|---|---|---|---|
| 2026 Q3 | 4 | 3.53 k | $143 k |
| 2026 Q2 | 237 | 122 M | $4.89 B |
| 2026 Q1 | 228 | 119 M | $3.73 B |
| 2025 Q4 | 215 | 122 M | $3.02 B |
| 2025 Q3 | 182 | 112 M | $1.82 B |
| 2025 Q2 | 187 | 119 M | $1.57 B |
| 2025 Q1 | 223 | 106 M | $2.33 B |
| 2024 Q4 | 217 | 99.0 M | $2.64 B |
| 2024 Q3 | 195 | 102 M | $2.71 B |
| 2024 Q2 | 148 | 102 M | $1.84 B |
| 2024 Q1 | 135 | 92.4 M | $1.69 B |
| 2023 Q4 | 122 | 80.8 M | $884 M |
| 2023 Q3 | 88 | 68.4 M | $392 M |
| 2023 Q2 | 99 | 69.5 M | $539 M |
| 2023 Q1 | 88 | 66.5 M | $443 M |
| 2022 Q4 | 95 | 67.1 M | $600 M |
| 2022 Q3 | 97 | 65.9 M | $649 M |
| 2022 Q2 | 79 | 51.0 M | $406 M |
| 2022 Q1 | 74 | 54.0 M | $524 M |
| 2021 Q4 | 59 | 50.3 M | $769 M |
| 2021 Q3 | 49 | 48.0 M | $796 M |
| 2021 Q2 | 47 | 47.9 M | $1.03 B |
| 2021 Q1 | 32 | 45.7 M | $1.48 B |